Last reviewed · How we verify

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. pipeline: 3 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 3 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Hemoporfin Hemoporfin marketed Other
Doxorubicin hydrochloride liposome Doxorubicin hydrochloride liposome marketed Anthracycline chemotherapy agent (liposomal formulation) DNA topoisomerase II Oncology
Hemoporfin PDT Hemoporfin PDT marketed Photosensitizer Porphyrin-based photosensitizer (non-receptor mediated) Oncology
FDA018-ADC FDA018-ADC phase 3 Antibody-drug conjugate (ADC) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. AstraZeneca · 1 shared drug class
  3. BioAtla, Inc. · 1 shared drug class
  4. Byondis B.V. · 1 shared drug class
  5. Charite University, Berlin, Germany · 1 shared drug class
  6. Gustave Roussy, Cancer Campus, Grand Paris · 1 shared drug class
  7. Jiaxing AnDiCon Biotech Co.,Ltd · 1 shared drug class
  8. Amgen · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-fudan-zhangjiang-bio-pharmaceutical-co-ltd. Accessed 2026-05-17.

Related